Cargando…

A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica

OBJECTIVE: As phase III trials have shown interest in innovative but expensive drugs in the treatment of neuromyelitis optica spectrum disorder (NMOSD), data are needed to clarify strategies in the treatment of neuromyelitis optica (NMO). This meta‐analysis compares the efficacy of first‐line strate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giovannelli, Jonathan, Ciron, Jonathan, Cohen, Mikael, Kim, Ho‐Jin, Kim, Su‐Hyun, Stellmann, Jan‐Patrik, Kleiter, Ingo, McCreary, Morgan, Greenberg, Benjamin M., Deschamps, Romain, Audoin, Bertrand, Maillart, Elisabeth, Papeix, Caroline, Collongues, Nicolas, Bourre, Bertrand, Laplaud, David, Ayrignac, Xavier, Durand‐Dubief, Françoise, Ruet, Aurélie, Vukusic, Sandra, Marignier, Romain, Dauchet, Luc, Zephir, Hélène
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528466/ https://www.ncbi.nlm.nih.gov/pubmed/34505407 http://dx.doi.org/10.1002/acn3.51451

Ejemplares similares

Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study
por: Demuth, Stanislas, et al.
Publicado: (2022)

Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?
por: Poullet, Zélia, et al.
Publicado: (2022)

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
por: Cobo-Calvo, Alvaro, et al.
Publicado: (2019)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica
por: Baert, Laurie, et al.
Publicado: (2021)

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
por: Ringelstein, Marius, et al.
Publicado: (2021)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
por: Schanda, Kathrin, et al.
Publicado: (2015)

The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab
por: Nicolas, Philippe, et al.
Publicado: (2019)

White Matter Atrophy and Cognitive Dysfunctions in Neuromyelitis Optica
por: Blanc, Frederic, et al.
Publicado: (2012)

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
por: Asgari, Nasrin, et al.
Publicado: (2017)

Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases
por: Avouac, Alexandre, et al.
Publicado: (2021)

Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)

Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: A multicenter cross-sectional study
por: Cobo-Calvo, Álvaro, et al.
Publicado: (2019)

Ependyma: a new target for autoantibodies in neuromyelitis optica?
por: Bigotte, Maxime, et al.
Publicado: (2022)

Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts
por: McCreary, M, et al.
Publicado: (2018)

Update on biomarkers in neuromyelitis optica
por: Melamed, Esther, et al.
Publicado: (2015)

Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid
por: Marignier, R., et al.
Publicado: (2016)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review
por: Papp, Viktoria, et al.
Publicado: (2021)

TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis
por: Hilezian, Frédéric, et al.
Publicado: (2021)

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
por: Januel, Edouard, et al.
Publicado: (2023)

Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders
por: Lebrun, Christine, et al.
Publicado: (2018)

Cranial nerve involvement in patients with MOG antibody–associated disease
por: Cobo-Calvo, Alvaro, et al.
Publicado: (2019)

Demographic and clinical features of neuromyelitis optica: A review
por: Pandit, L, et al.
Publicado: (2015)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
por: Hor, Jyh Yung, et al.
Publicado: (2020)

Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder
por: Thöne, Jan, et al.
Publicado: (2018)

Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability
por: Cobo-Calvo, Alvaro, et al.
Publicado: (2020)

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
por: Fujihara, Kazuo, et al.
Publicado: (2020)

Immunoadsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder
por: Heigl, Franz, et al.
Publicado: (2023)

Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis Optica
por: Chanson, Jean-Baptiste, et al.
Publicado: (2013)

Ruxolitinib treatment in a patient with neuromyelitis optica: A case report
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023)

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
por: Lebrun-Frénay, Christine, et al.
Publicado: (2021)

Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
por: Stellmann, Jan-Patrick, et al.
Publicado: (2017)

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
por: Marignier, Romain, et al.
Publicado: (2021)

Unusual neurologic presentation of aseptic abscesses syndrome
por: Nicolas, Philippe, et al.
Publicado: (2018)

Retinal Optical Coherence Tomography in Neuromyelitis Optica
por: Oertel, Frederike Cosima, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b5od0ob39iv6aeu5mg644ru3km